期刊文献+

高效液相色谱法测定唑来膦酸中的磷酸盐和亚磷酸盐 被引量:8

Determination of Phosphate and Phosphite in Zoledronic Acid by HPLC
下载PDF
导出
摘要 建立了测定唑来膦酸中磷酸盐和亚磷酸盐的高效液相色谱法。以IC-PAK色谱柱为固定相,以体积分数0.07%的甲酸溶液(用1 mol/L氢氧化钠溶液调节pH至3.5)为流动相,采用折光检测器检测唑来膦酸样品。唑来膦酸、磷酸盐和亚磷酸盐3组分分离完全,检测限分别为15,20和15 ng,线性关系良好,相对标准偏差均小于1%。该方法简便、准确,适用于唑来膦酸中磷酸盐和亚磷酸盐的测定。 A new analytical method based on high performance liquid chromatography (HPLC) was obtained for the determination of phosphate and phosphite in zoledronic acid. The chromato- graphic separation of zoledronic acid sample was achieved on an IC-PAK column with a refractive index detector. The mobile phase was composed of 0.07% formic acid and the pH was adjusted to 3.5 with 1 mol/L sodium hydroxide solution. Zoledronic acid, phosphate and phosphite were completely separated and the detection limits were 15 ng, 20 ng and 15 ng respectively. The calibration curves showed good linearity, and the relative standard deviations (RSD) were less than 1%. The method is simple, accurate and suitable for the determination of phosphate and phosphite in zoledronic acid.
出处 《淮海工学院学报(自然科学版)》 CAS 2010年第4期40-42,共3页 Journal of Huaihai Institute of Technology:Natural Sciences Edition
关键词 高效液相色谱法 唑来膦酸 磷酸盐 亚磷酸盐 HPLC zoledronic acid phosphate phosphite
  • 相关文献

参考文献6

二级参考文献27

  • 1谷铣之 殷蔚伯 刘泰福 等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2002.565-568.
  • 2[2]Rosen LS,Gordon D,Kaminski M,et al.Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma:a randomized,double-blind,multicenter,comparative trial[J].Cancer,2003,98:1735.
  • 3[3]Algur E,Roger MD,Macklis M,et al.Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines[J].Int J Radiat Oncol Biol Phys,2005,61:5 35-542.
  • 4[1]Body JJ. Clinical research update: zoledronate [J]. Cancer, 1997,80 (1): 699.
  • 5[2]Berenson JR, Vescio R, Henick K, et al. A phase I , open label,dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonte, in cancer patients with metastatic bone disease [J].Cancer, 2001, 91(1): 144.
  • 6[3]Gschaidmeier H, Faerber L, Schloesser A, et al. Zoledronic acid,a highly potent bisphosphonate compound, exhibits anti-angiogenic properties that may confer additional benefit in the treatment of cancer patients[J]. Ann Oncol, 2000, 11(Suppl 4): Abst 32PD.
  • 7[4]Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compoud [J].J Bone Miner Res, 1994, 9: 745.
  • 8[5]Pataki A, Müller K, Green JR, et al. Effects of short-term treatment with the bisphosphontes zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment [J]. Anat Rec,1997, 249: 458.
  • 9[6]Green J, Gschaidmeier H, Yoneda T, et al. Zoledronic acid potently inhibits umour-induced osteolyis in two models of breast cancer metastasis to bone[J]. Ann Oncol, 2000, 11(Suppl 4):Abst 50P.
  • 10[7]Glatt M. Treatment with zoledronate or SDZ PTS 893 restores trabecular architecture in OVX mice [J]. Osteoporosis Int, 2000,11(Suppl 2): Abst 465.

共引文献26

同被引文献75

引证文献8

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部